CPHI Milan
Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to CPHI Milan 2024
read morePeople & Career | News |
Our products and services are essential components for the research, development and production of new generation medicines as for example vaccines, immuno-oncology therapies, and protein replacement treatments.
Discover our latest initiatives, technology advancements, expansion plans, and our ongoing commitment to research and development of cutting-edge solutions for Cell & Gene Therapies and Nucleic Acids.
Anemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to CPHI Milan 2024
read moreDiscover the pivotal role of plasmid DNA sequencing in advancing gene therapy. Learn how this groundbreaking technology is driving the development of novel treatments and shaping the future of biomedicine.
read moreAnemocyte Brings Italian Excellence in the Cell and Gene Therapy Sector to ATE24 Lisbon, Portugal
read moreDownstream process is fine tuned to recover the soluble fraction of plasmidic DNA, whereas the genomic DNA, proteins polysaccharides and total RNA from E. coli cells are precipitated and removed by depth filtration.
read moreA plasmid is a circular double-stranded DNA molecule that exists separately from the chromosomal DNA within a cell.
read moreThe utilization of plasmid DNA in the production of viral vectors for gene therapy represents a critical advancement in medical biotechnology.
read moreLentiviruses and adeno-associated viruses (AAV) require specific plasmids for their production, which ensure efficient vector generation and safe delivery of the gene of interest (GOI).
read moreMany people first became familiar with the term “mRNA” when COVID-19 vaccines were rolled out. In the simplest terms, mRNA, which stands for messenger ribonucleic acid, is a genetic material that instructs the cells to make specific proteins.
read moreBIO International Convention 3-6 june 2024 | San Diego. Meet us at Italian Pavilion at booth #3623(Anemocyte table, H).
read moreWhat’s new with the ICH Q14 for Analytical development?To regulate drug production, there are a multitude of documents that pharmaceutical companies can refer
read moreAnemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131
VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961